Articles, guides, and regulatory updates from our community.
Systematic review of 142 studies reveals newer antidiabetic drugs are generally cost-effective, though access varies by income level and drug pricing.
By Peptide Association Research Team
Systematic review of 142 studies reveals newer diabetes drugs show cost-effectiveness, but affordability varies by country income levels and treatment timing.
By Peptide Association Research Team
New research reveals alarming connections between childhood obesity and cardiovascular disease. Study examines 381 million affected children worldwide.
By Peptide Association Research Team
The GLP-1 revolution has rewritten the rules of obesity treatment. How incretin-based peptide therapies achieve what diet and exercise alone cannot — and what comes next.
By Peptide Association Editorial Team